Speech-Language Pathologists in Bellbrook, OH Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Julie Lyn Buzzard, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1957 N Lakeman Dr, Bellbrook, OH 45305 Phone: 937-848-7800

Jane Worth, B.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3924 Dane Ct, Bellbrook, OH 45305 Phone: 937-623-6791

Kayleigh Izor Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3757 Upper Bellbrook Rd, Bellbrook, OH 45305 Phone: 937-938-0493

Molly Simpson Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3600 Feedwire Rd, Bellbrook, OH 45305 Phone: 937-848-2141

Melissa Wallace Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3757 Upper Bellbrook Rd, Bellbrook, OH 45305 Phone: 937-848-5001

Mrs. Denise Davis Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3757 Upper Bellbrook Rd, Bellbrook, OH 45305 Phone: 937-848-6251    Fax: 937-848-5018

Hannah Ruth Reckman Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 60 E South St, Bellbrook, OH 45305 Phone: 937-767-6142

Emma Jacky Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3757 Upper Bellbrook Rd, Bellbrook, OH 45305 Phone: 937-848-5001

News Archive

XJB-5-131 prevents secondary damage of severe traumatic brain injury

Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.

FDA warning letter to Genzyme related to Allston manufacturing facility

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the FDA warning letter issued to Genzyme addressing deficiencies related to Genzyme's Allston Landing manufacturing facility during an inspection performed in September and October 2008 has no foreseeable impact on the supply of Aldurazyme.

China releases updated statistics on HIV/AIDS

"A total of 28,000 people died of HIV/AIDS in China in 2011, and another 48,000 in the country were found newly infected by the virus, according to an official publication" released on Saturday by China's Ministry of Health, UNAIDS, and the WHO, Xinhua/China Daily reports.

About 26% of U.S. girls, women ages 14 to 59 have HPV

Of U.S. women and girls ages 14 to 59, about 24.9 million women, or 26.8%, have the human papillomavirus, and about 2% of women and girls in the age group have HPV strains 16 or 18, which together cause about 70% of cervical cancer cases, according to a study published in the Feb. 28 issue of the Journal of the American Medical Association, the Wall Street Journal reports.

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

Read more Medical News

› Verified 4 days ago